UCB SA (UNC.DE) Stock Price & Overview
FRA:UNC • BE0003739530
Current stock price
The current stock price of UNC.DE is 273.6 EUR. Today UNC.DE is up by 2.7%. In the past month the price increased by 9.79%.
UNC.DE Key Statistics
- Market Cap
- 53.218B
- P/E
- 27.39
- Fwd P/E
- 25.91
- EPS (TTM)
- 9.99
- Dividend Yield
- 0.37%
UNC.DE Stock Performance
UNC.DE Stock Chart
UNC.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to UNC.DE.
UNC.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to UNC.DE. UNC.DE gets an excellent profitability rating and is at the same time showing great financial health properties.
UNC.DE Earnings
On February 26, 2026 UNC.DE reported an EPS of 6.46 and a revenue of 4.25B. The company beat EPS expectations (17.63% surprise) and beat revenue expectations (13.65% surprise).
UNC.DE Forecast & Estimates
27 analysts have analysed UNC.DE and the average price target is 265 EUR. This implies a price decrease of -3.14% is expected in the next year compared to the current price of 273.6.
For the next year, analysts expect an EPS growth of 5.7% and a revenue growth 11.6% for UNC.DE
UNC.DE Groups
Sector & Classification
UNC.DE Financial Highlights
Over the last trailing twelve months UNC.DE reported a non-GAAP Earnings per Share(EPS) of 9.99. The EPS increased by 100.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.13% | ||
| ROA | 8.58% | ||
| ROE | 14.34% | ||
| Debt/Equity | 0.2 |
UNC.DE Ownership
UNC.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.4 | 97.617B | ||
| SAN | SANOFI | 9.36 | 97.205B | ||
| SNW | SANOFI | 9.36 | 97.193B | ||
| UCB | UCB SA | 26.04 | 53.49B | ||
| MRK | MERCK KGAA | 14.18 | 48.63B | ||
| 1MRK | MERCK KGAA | 13.62 | 46.695B | ||
| 1BAYN | BAYER AG-REG | 9.21 | 39.808B | ||
| BAYN | BAYER AG-REG | 9.12 | 39.415B | ||
| IPN | IPSEN | 13.49 | 14.315B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.43 | 10.214B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 10.059B | ||
| VIRP | VIRBAC SA | 16.83 | 3.02B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About UNC.DE
Company Profile
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 10,117 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Company Info
IPO: 1987-01-02
UCB SA
Allee de la Recherche, 60
Anderlecht BRUXELLES-CAPITALE BE
Employees: 9765
Phone: 3225599999
UCB SA / UNC.DE FAQ
Can you describe the business of UCB SA?
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 10,117 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
What is the current price of UNC stock?
The current stock price of UNC.DE is 273.6 EUR. The price increased by 2.7% in the last trading session.
Does UNC stock pay dividends?
UCB SA (UNC.DE) has a dividend yield of 0.37%. The yearly dividend amount is currently 1.39.
What is the ChartMill technical and fundamental rating of UNC stock?
UNC.DE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the GICS sector and industry of UNC stock?
UCB SA (UNC.DE) operates in the Health Care sector and the Pharmaceuticals industry.
Would investing in UCB SA be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on UNC.DE.
Can you provide the market cap for UCB SA?
UCB SA (UNC.DE) has a market capitalization of 53.22B EUR. This makes UNC.DE a Large Cap stock.